Market capitalization | $5.20m |
Enterprise Value | $1.80m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 30.00 |
P/S ratio (TTM) P/S ratio | 86.67 |
P/B ratio (TTM) P/B ratio | 1.99 |
Revenue growth (TTM) Revenue growth | -67.76% |
Revenue (TTM) Revenue | $60.00k |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
2 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:
2 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:
Sep '23 |
+/-
%
|
||
Net Profit | -19 -19 |
37%
37%
|
|
Depreciation and Amortization | 0.08 0.08 |
11%
11%
|
|
Stock Compensation | 0.25 0.25 |
72%
72%
|
|
Operating Cash Flow | -21 -21 |
23%
23%
|
|
Investments | 0.44 0.44 |
51%
51%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -21 -21 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.
Head office | United States |
CEO | Pankaj Mohan |
Employees | 12 |
Founded | 2011 |
Website | www.sonnetbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.